Berthold, Oliver http://orcid.org/0000-0002-3442-7569
Clemens, Vera
Witt, Andreas
Brähler, Elmar
Plener, Paul L.
Fegert, Jörg M.
Article History
Received: 30 January 2019
Revised: 4 June 2019
Accepted: 8 June 2019
First Online: 18 June 2019
Competing interests
: P.L.P. has received research funding from the Bundesinstitut für Arzneimittel und Medizinprodukte, BMBF (Federal Ministry of Education and Research), VW-Foundation, Baden-Württemberg Stiftung, Lundbeck, and Servier. P.L.P. holds no stocks of pharmaceutical companies. Within the past five years, J.M.F. received research funding from the European Union (EU), German Research Foundation (DFG), the German Federal Ministry of Health (BMG), the German Federal Ministry of Education and Research (BMBF), the German Federal Ministry of Family Affairs, Senior Citizens, Women and Youth (BMFSFJ), several state ministries of social affairs, State Foundation Baden-Württemberg, Volkswagen Foundation, European Academy, Pontifical Gregorian University, RAZ, CJD, Caritas, and Diocese of Rottenburg-Stuttgart. He has received travel grants, honoraria and sponsoring for conferences and medical educational purposes from the German Research Foundation (DFG), the American Academy of Child and Adolescent Psychiatry (AACAP), the National Institute of (Mental) Health (NIMH/NIH), the European Union (EU), Pro Helvetica, Janssen-Cilag (J&J), Shire, several universities, professional associations, and German federal and state ministries. He has conducted clinical trials for Janssen-Cilag, Lundbeck, the German Federal Ministry of Education and Research (BMBF) and Servier. He is in steering committees and DSMB for Lundbeck, Servier. Every grant and honorarium has to be declared to the law office of the University hospital Ulm. Potential conflicts of interests have to be declared to German Society for Child and Adolescent Psychiatry and Psychotherapy (DGKJP) and American Academy of Child and Adolescent Psychiatry (AACAP) annually, because of commission membership. He has no stocks, no interests in pharmaceutical companies, and is a majority owner of the 3Li institute. The other authors declare no competing interests.